Please login to the form below

Not currently logged in
Email:
Password:

Votrient

This page shows the latest Votrient news and features for those working in and with pharma, biotech and healthcare.

Home-grown colorectal cancer drug approved in China

Home-grown colorectal cancer drug approved in China

Meanwhile, other orally-active drugs that target VEGF – including Bayer’s Nexavar (sorafenib), Novartis’ Votrient (pazopanib), and Sanofi’s Caprelsa (vandetanib) – have been developed for a range of other solid tumours

Latest news

More from news
Approximately 2 fully matching, plus 27 partially matching documents found.

Latest Intelligence

  • Pharma deals during April 2014 Pharma deals during April 2014

    Additional GSK products include the VEGFR inhibitor, Votrient (renal cell carcinoma), Tykerb (HER2 metastatic breast cancer), Arzerra (chronic lymphocytic leukaemia) and Promacta (thrombocytopenia). GSK will continue with its immunotherapy and

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics